Core Viewpoint - Skye Bioscience, Inc. is set to discuss its 2024 fourth quarter and full-year financial results in a conference call on March 20, 2025, indicating a focus on transparency and investor engagement [1][2]. Company Overview - Skye Bioscience is a clinical-stage biotechnology company dedicated to developing new therapeutic pathways for obesity and metabolic health disorders through next-generation molecules that modulate G-protein coupled receptors [3]. - The company is conducting a Phase 2 clinical trial for nimacimab, an antibody that inhibits CB1, and is also exploring its combination with a GLP-1R agonist (Wegovy®) [3]. Financial Communication - An earnings press release will be issued after market close on March 20, 2025, and a live webcast of the conference call will be available on the Skye Investor Relations website [1][2].
Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025